News

• 18/11/2024

  APPOINTMENT OF INTERIM CHIEF FINANCIAL OFFICER

  ↓ DOWNLOAD PDF
• 11/09/2024

  ARECOR PRESENTS POSITIVE DATA FROM PHASE I CLINICAL TRIAL OF AT278 IN LATE-BREAKING ORAL PRESENTATION AT EASD 2024

  ↓ DOWNLOAD PDF
• 03/09/2024

  ARECOR ANNOUNCES ORAL PRESENTATION OF POSITIVE AT278 PHASE 1 CLINICAL DATA AT THE EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES 2024

  ↓ DOWNLOAD PDF
• 21/05/2024

  ARECOR TO HOST COMPANY AND KOL WEBINAR TODAY TO DISCUSS CLINICAL TRIAL RESULTS FOR ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN AT278 DEMONSTRATING SUPERIORITY IN PEOPLE WITH TYPE 2 DIABETES

  ↓ DOWNLOAD PDF
• 20/05/2024

  AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN DEMONSTRATES SUPERIORITY IN PHASE I CLINICAL TRIAL IN OVERWEIGHT AND OBESE PEOPLE WITH TYPE 2 DIABETES

  ↓ DOWNLOAD PDF
• 09/05/2024

  ARECOR AND MEDTRONIC DIABETES ESTABLISH COLLABORATION TO DEVELOP A NOVEL THERMOSTABLE INSULIN FOR IMPLANTABLE PUMP DELIVERY

  ↓ DOWNLOAD PDF
• 12/03/2024

  ARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED BIOAVAILABILITY

  ↓ DOWNLOAD PDF
• 29/02/2024

  ARECOR ANNOUNCES LAUNCH OF OGLUO® IN THE NETHERLANDS

  ↓ DOWNLOAD PDF
• 23/01/2024

  ARECOR ANNOUNCES UPDATE ON INBRX-101

  ↓ DOWNLOAD PDF
• 18/01/2024

  ARECOR GRANTED KEY EUROPEAN PATENT EXTENDING PROTECTION FOR INSULIN PRODUCTS, AT278 AND AT247

  ↓ DOWNLOAD PDF
• 08/01/2024

  ARECOR ANNOUNCES EXPANSION OF EXISTING SPECIALTY HOSPITAL FORMULATION COLLABORATION

  ↓ DOWNLOAD PDF
• 03/01/2024

  ARECOR APPOINTS DR HELEN PARRIS AS SVP, COMMERCIAL & GENERAL MANAGER OF TETRIS PHARMA LTD.

  ↓ DOWNLOAD PDF